![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Active Filter(s):
Details:
Advanced Accelerator Applications (AAA) and Endocyte, Inc., both Novartis companies, successfully completed full-scale development of Pluvicto and also received Breakthrough Therapy designation from the U.S. FDA last year.
Lead Product(s): Lutetium-177 Vipivotide Tetraxetan
Therapeutic Area: Oncology Product Name: Pluvicto
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Advanced Accelerator Applications
Deal Size: $172.0 million Upfront Cash: $12.0 million
Deal Type: Agreement March 29, 2022